South African HIV-1 vaccine candidates - The journey from the bench to clinical trials

South African Medical Journal

Volumn 102, Issue 6, 2012, Pages 452-455

  Williamson, Anna Lise ^a   Rybicki, Ed ^a   Shephard, Enid ^b   Gray, Glenda ^c   Bekker, Linda Gail ^a   Downing, Katrina ^a   Williamson, Carolyn ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; ERDOSTEINE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; MIFAMURTIDE; NEF PROTEIN; RNA DIRECTED DNA POLYMERASE; SAAVI DNA C2 VACCINE; SAAVI MVA C VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMIAN IMMUNODEFICIENCY VIRUS; SOUTH AFRICA; VACCINATION; VIRUS CHARACTERIZATION; CLINICAL TRIAL (TOPIC); HISTORY; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; UNIVERSITY;

AIDS VACCINES; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; SOUTH AFRICA; UNIVERSITIES;

EID: 84865120101     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/samj.5668     Document Type: Article

References (21)

1. UNAIDS. Report on the global AIDS epidemic 2010. http://www.unaids.org/documents/20101123_globalreport_em.pdf (accessed February 2012).
2. Morens DM, Holmes EC, Davis AS, Taubenberger JK. Global rinderpest eradication: lessons learned and why humans should celebrate too. J Infect Dis 2011;204(4):502-505. [http://dx.doi.org/10.1093/infdis/jir327]
3. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010;362(4):289-298. [http://dx.doi.org/10.1056/NEJMoa0904797]
4. Ncayiyana DJ. SAAVI HIV vaccine trials-one small step for humankind. S Afr Med J 2009;99(10):683.
5. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001;58:19-42.
6. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010;5(5):428-434. [http://dx.doi.org/10.1097/COH]
7. Williamson C, Morris L, Maughan MF, et al. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses 2003;19(2):133-144. [http://dx.doi.org/10.1089/088922203762688649]
8. Newman MJ. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses. Curr Opin Investig Drugs 2002;3(3):374-378.
9. Burgers WA, Chege GK, Muller TL, et al. Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 2009;90(Pt 2):468-480. [http://dx.doi.org/10.1099/vir.0.004614-0]
10. Burgers WA, Shephard E, Monroe JE, et al. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses 2008;24(2):195-206. [http://dx.doi.org/10.1089/aid.2007.0205]
11. Chege GK, Shephard EG, Meyers A, et al. HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. J Gen Virol 2008;89(Pt 9):2214-2227. [http://dx.doi.org/10.1099/vir.0.83501-0]
12. Jaffray A, Shephard E, van Harmelen JH, Williamson C, Williamson AL, Rybicki EP. Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. J Gen Virol 2004;85(Pt 2):409-413.
13. Chege GK, Thomas R, Shephard EG, et al. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine 2009;27(35):4857-4866. [http://dx.doi.org/10.1016/j.vaccine.2009.05.064]
14. Halsey RJ, Tanzer FL, Meyers A, et al. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. Virus Res 2008;133(2):259-268. [http://dx.doi.org/10.1016/j.virusres.2008.01.012]
15. Pillay S, Shephard EG, Meyers AE, Williamson AL, Rybicki EP. HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice. J Immune Based Ther Vaccines 2010;8:7. [http://dx.doi.org/10.1186/1476-8518-8-7]
16. Tanzer FL, Shephard EG, Palmer KE, Burger M, Williamson AL, Rybicki EP. The porcine circovirus type 1 capsid gene promoter improves antigen expression and immunogenicity in a HIV-1 plasmid vaccine. Virol J 2011;8(1):51. [http://dx.doi.org/10.1186/1743-422X-8-51]
17. Shen YJ, Shephard E, Douglass N, et al. A novel candidate HIV vaccine vector based on the replication deficient capripoxvirus, lumpy skin disease virus (LSDV). Virol J 2011;8:265. [http://dx.doi.org/10.1186/1743-422X-8-265]
18. Chin'ombe N, Bourn WR, Williamson AL, Shephard EG. Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice. Virol J 2009;6:87. [http://dx.doi.org/10.1186/1743-422X-6-87]
19. Meyers A, Chakauya E, Shephard E, et al. Expression of HIV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol 2008;8:53. [http://dx.doi.org/10.1186/1472-6750-8-53]
20. Burgers WA, van Harmelen JH, Shephard E, et al. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J Gen Virol 2006;87(Pt 2):399-410. [http://dx.doi.org/10.1099/vir.0.81379-0]
21. Gray G, Elizaga M, Bekker LG, et al. Immunogenicity of a Subtype C HIV Vaccine Regimen, the SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine: Results of a Phase I Study Conducted in South Africa and USA Amongst HIV Uninfected Adults (HVTN 073/SAAVI 102). Conference on Retroviruses and Opportunistic Infections (CROI) 2011, Boston, USA.